^
Association details:
| Biomarker: | EBF1-PDGFRB fusion |
|---|---|
| Cancer: | Childhood B Acute Lymphoblastic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Excerpt:
Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib…
DOI:
https://dx.doi.org/10.1056%2FNEJMoa1403088
